Analysis of thromboembolic events in head and neck cancer patients who underwent concurrent chemoradiotherapy with cisplatin

Mostrar otras versiones (1)

BACKGROUND/AIMS: The study investigated the incidence of thromboembolic events (TEE) in head and neck (H&N) cancer patients who received concurrent chemoradiotherapy (CCRT) with cisplatin, and analyzed the factors affecting TEE occurrence METHODS: Two hundred and fifty-seven patients who started...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Hundo, Choi, Jin-Hyuk, Kang, Seok Yun, Lee, Hyun Woo, Choi, Yong Won, Kim, Tae-Hwan, Ahn, Mi Sun, Kim, Chul-Ho, Shin, Yoo Seob, Jang, Jeon Yeob, Oh, Young-Taek, Heo, Jaesung, Sheen, Seung Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Association of Internal Medicine 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9082433/
https://www.ncbi.nlm.nih.gov/pubmed/35439872
http://dx.doi.org/10.3904/kjim.2021.309
Descripción
Sumario:BACKGROUND/AIMS: The study investigated the incidence of thromboembolic events (TEE) in head and neck (H&N) cancer patients who received concurrent chemoradiotherapy (CCRT) with cisplatin, and analyzed the factors affecting TEE occurrence METHODS: Two hundred and fifty-seven patients who started CCRT with cisplatin for H&N cancer from January 2005 to December 2019 were analyzed. RESULTS: TEE occurred in five patients, an incidence rate of 1.9%. The 2-, 4-, and 6-month cumulative incidences of TEE were 0.8%, 1.6%, and 1.9%, respectively. Khorana score was the only factor associated with TEE occurrence (p = 0.010). CONCLUSIONS: The incidence of TEE in H&N cancer patients who underwent CCRT with cisplatin was relatively low when compared to other types of cancer. However, patients with a high Khorana score require more careful surveillance for possible TEE occurrence.

Ejemplares similares